We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.2B
AUM Growth
+$62.1M
(+2%)
Cap. Flow
+$623M
Cap. Flow
% of AUM
19.5%
Top 10 Holdings %
Top 10 Hldgs %
58.79%
Holding
97
New
22
Increased
20
Reduced
15
Closed
11
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
+$158M |
| 2 |
Zai Lab
ZLAB
|
+$107M |
| 3 |
Arvinas
ARVN
|
+$93.6M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$70.9M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$59.4M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
+$81.7M |
| 2 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
+$77.3M |
| 3 |
Arcus Biosciences
RCUS
|
+$75.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$63.6M |
| 5 |
ITOS
iTeos Therapeutics
ITOS
|
+$44.7M |
Sector Composition
| 1 | Healthcare | 99.16% |
| 2 | Financials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$450M
| $424M | 13.25% |
11,584,280
+300,000
| +3% | +$10.8M |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $263M | 8.24% |
5,183,431
+1,149,549
| +28% | +$50.7M |
|
|
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
| $198M | 6.2% |
3,195,624
+971,221
| +44% | +$59.4M |
|
4
AnaptysBio
ANAB
$1.69B
| $186M | 5.82% |
7,521,024
| – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.84B
| $162M | 5.06% |
+2,069,634
| New | +$158M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $159M | 4.96% |
3,951,566
| – | – |
|
|
7
Acadia Pharmaceuticals
ACAD
$4.44B
| $145M | 4.54% |
5,991,479
+2,930,886
| +96% | +$70.9M |
|
8
Xencor
XNCR
$1.11B
| $133M | 4.15% |
4,968,756
+62,650
| +1% | +$2.02M |
|
9
Kura Oncology
KURA
$1B
| $107M | 3.34% |
6,638,371
+2,913,934
| +78% | +$42.1M |
|
|
10
Arcus Biosciences
RCUS
$3.52B
| $103M | 3.22% |
3,265,101
-2,258,257
| -41% | -$75.7M |
|
|
11
Arvinas
ARVN
$535M
| $101M | 3.17% |
1,503,929
+1,373,629
| +1,054% | +$93.6M |
|
|
12
Zai Lab
ZLAB
$2.31B
| $97.8M | 3.06% |
+2,223,212
| New | +$107M |
|
13
Alector
ALEC
$167M
| $81.8M | 2.56% |
5,738,448
+743,478
| +15% | +$11.8M |
|
14
Nuvation Bio
NUVB
$2.03B
| $73.1M | 2.29% |
13,896,543
| – | – |
|
15
Relay Therapeutics
RLAY
$4.25B
| $68.6M | 2.15% |
2,291,441
+512,357
| +29% | +$12.4M |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $64.7M | 2.02% |
+1,975,611
| New | +$58.6M |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $59.6M | 1.87% |
3,495,943
+1,578,880
| +82% | +$26.8M |
|
|
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $57.6M | 1.8% |
+1,646,260
| New | +$48.1M |
|
|
RNAM
19
DELISTED
Avidity Biosciences
RNAM
| $51M | 1.59% |
2,759,505
| – | – |
|
20
Atea Pharmaceuticals
AVIR
$384M
| $45.8M | 1.43% |
6,340,639
+964,505
| +18% | +$6.55M |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $41.2M | 1.29% |
+500,622
| New | +$51.2M |
|
22
argenx
ARGX
$54.2B
| $39.4M | 1.23% |
+125,000
| New | +$36.3M |
|
23
Design Therapeutics
DSGN
$848M
| $38.3M | 1.2% |
2,371,445
+218,448
| +10% | +$3.35M |
|
24
Revolution Medicines
RVMD
$39.3B
| $32.5M | 1.02% |
+1,274,097
| New | +$27.7M |
|
25
Vaxcyte
PCVX
$8.12B
| $31.5M | 0.99% |
1,304,741
+1,283,941
| +6,173% | +$28.1M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM